Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
Stefania Trino(Centro di Riferimento Oncologico della Basilicata), Giovanni Martinelli(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Annalisa Lonetti(University of Bologna), Luciana De Luca(European Union), Domenico Russo(University of Brescia), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Pellegrino Musto(University of Bari Aldo Moro), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ilaria Iacobucci(St. Jude Children's Research Hospital), Federica Cattina(University of Brescia), Daniela Erriquez(University of Bologna), Giovanni Perini(University of Bologna), Enrico Derenzini(University of Milan), Claudia Venturi(University of Bologna), Ilaria Laurenzana(Centro di Riferimento Oncologico della Basilicata)
Cited by 35
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627